公开(公告)号：US20210363234A1

公开(公告)日：2021-11-25

申请号：US17325743

申请日：2021-05-20

Applicant: Janssen Biotech, Inc.

Inventor： Mathew Germinaro ,  Christopher O'Brien ,  Jacqueline Perrigoue ,  Marion Vetter

IPC: C07K16/24 ,  A61P1/04 ,  A61P37/02

Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).

公开(公告)号：US12258393B2

公开(公告)日：2025-03-25

申请号：US17325743

申请日：2021-05-20

Applicant: Janssen Biotech, Inc.

Inventor： Matthew Germinaro ,  Christopher O'Brien ,  Jacqueline Perrigoue ,  Marion Vetter

IPC: A61K39/00 ,  A61P1/04 ,  A61P37/02 ,  C07K16/24

Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor, such as an anti-TNF-α antibody (e.g., golimumab).

公开(公告)号：US20220372129A1

公开(公告)日：2022-11-24

申请号：US17748629

申请日：2022-05-19

Applicant: Janssen Biotech, Inc.

Inventor： Matthew Germinaro ,  Christopher O'Brien ,  Jacqueline Perrigoue ,  Marion Vetter

IPC: C07K16/24 ,  A61P1/04 ,  A61K38/17 ,  A61K39/395

Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNFα inhibitor, such as an anti-TNFα antibody (e.g., golimumab).